Preventing Rectal SHIV Transmission in Monkeys with Antiretroviral Drugs
Author Information
Author(s): GarcĂa-Lerma J. Gerardo, Otten Ron A, Qari Shoukat H, Jackson Eddie, Cong Mian-er, Masciotra Silvina, Luo Wei, Kim Caryn, Adams Debra R, Monsour Michael, Lipscomb Jonathan, Johnson Jeffrey A, Delinsky David, Schinazi Raymond F, Janssen Robert, Folks Thomas M, Heneine Walid
Primary Institution: Centers for Disease Control and Prevention
Hypothesis
Can pre-exposure prophylaxis (PrEP) with antiretroviral drugs effectively prevent rectal transmission of SHIV in macaques?
Conclusion
The study found that both daily and intermittent PrEP with antiretroviral drugs can effectively protect against rectal SHIV transmission in macaques.
Supporting Evidence
- All macaques receiving both FTC and high-dose tenofovir were protected from infection.
- Daily PrEP with FTC was found to be partially protective.
- Intermittent PrEP was as effective as daily PrEP in preventing SHIV transmission.
Takeaway
Giving monkeys medicine before they are exposed to a virus can help keep them from getting sick, just like how some people take medicine to avoid getting sick from germs.
Methodology
The study used a repeat-exposure macaque model with 14 weekly rectal virus challenges and compared different PrEP regimens.
Potential Biases
The staggered treatment groups may introduce bias, although all procedures were standardized.
Limitations
The doses of tenofovir used may be higher than safe for humans, and the study was conducted in a controlled animal model.
Participant Demographics
Rhesus macaques were used in the study.
Statistical Information
P-Value
0.008
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website